Journals / Journal of Clinical and Experimental Investigations / 2018 / Cilt: 9 Sayı: 2

Meme ve Jinekolojik Kanserli Hastalarda Kemoterapi Öncesi HBsAg, Anti-HBs ve İzole Anti -HBc Pozitiflik Oranları

Pages
91–94
Publication Date
2018-06-13
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Amaç: Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir.
📊
Key Findings & Data:Amaç: Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir.
💡
Conclusion & Impact:Amaç: Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:HBV · kemoterapi · kanser

Abstract

Amaç: Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir.

🔖

Cite This Article

İnci, A. (2018). Meme ve Jinekolojik Kanserli Hastalarda Kemoterapi Öncesi HBsAg, Anti-HBs ve İzole Anti -HBc Pozitiflik Oranları. Journal of Clinical and Experimental Investigations, Cilt: 9 Sayı: 2, 91–94. https://doi.org/10.5799/jcei.433817

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. İnci A, Fincancı M, Kalafat UM. Relation of HBeAg status with ALT, DNA level and liver histology in Chronic Hepathitis B patients. Viral Hepat J. 2015;21: 52-5.
  2. Wang Y, Luo XM, Yang D, et al. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol. 2013;19:923-30.
  3. Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-37.
  4. Engin B, Günay S, Binicier ÖM, Derviş Hakim G,Yıldız C, Paköz ZB. İmmünsüpresif hastalarda hepatit B virüs tarama sıklığı ve gerçek yaşam verileri.FNG & Bilim Tıp Dergisi 2016;2:256-9.
  5. Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22:6484- 500.
  6. Bozza C, Cinausero M, Iacono D, Puglisi F. Hepatitis B and cancer: A practical guide for the oncologist. Crit Rev Oncol Hematol. 2016;98:137- 46.
  7. Wu YT, Li X, Liu ZL, et al. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. PLoSOne. 2017;22;12:e0179680.
  8. Meidani M, Rostami M, Hemmati S, et al. Screening and evaluation of chronic and occult Hepatitis B in chemo - radiotherapy patients with cancer. Adv Biomed Res. 2016;5:85.
  9. Hwang JP, Artz AS, Somefield MR. Hepatitis b virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015;11:e487-9.
  10. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28:379-84.
  11. Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol. 2009;26:386-92.
  12. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol. 2010;17:32–8.
  13. Kose Ş, Olmezoglu A, Gozaydin A,Ece G. Seroprevalence of Hepatitis B and C among Oncology Patients in Turkey. J Health Popul Nutr. 2011 Dec; 29: 652–5.
  14. Engin B, Günay S, Binicier ÖB, Derviş Hakim G, Yıldız C, Paköz ZB. İmmünsüpresif hastalarda hepatit B virüs tarama sıklığı ve gerçek yaşam verileri. FNG & Bilim Tıp Dergisi 2016;2:256-9. 15. Oguz A, Aykas F, Unal D, et al. Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy. Asian Pac J Cancer Prev. 2014;15:1411-4.
  15. Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H, Hu HD. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015;114:164-73.
  16. Liu Z, Jiang L, Liang G, et al. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat. 2017;24:561-72.
  17. Kaya S, Tabak F. İnaktif HbsAg Taşıyıcılığı. Viral Hepatit 2018 1. baskı Kitabı,sayfa: 177-83.
  18. Toy M, Önder FO, Wörmann T, Bozdayi AM, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;12:337- 49.
  19. İnci A, Çavuş E, Altay G, et al. İstanbul’da Bir Eğitim ve Araştırma Hastanesi’ne Başvuran Hastalarda, Anti-HBs, Anti-HCV Seroprevalansı. İKSST Derg 2015:7:22-25.
  20. Engin B, Günay S, Binicier ÖM, Derviş Hakim G,Yıldız C, Paköz ZB. İmmünsüpresif hastalarda hepatit B virüs tarama sıklığı ve gerçek yaşam verileri.FNG & Bilim Tıp Dergisi 2016;2:256-9.
  21. Kose Ş, Olmezoglu A, Gozaydin A,Ece G. Seroprevalence of Hepatitis B and C among Oncology Patients in Turkey. J Health Popul Nutr. 2011 Dec; 29: 652–5.